© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Glycoprotein IIIa polymorphism and risk of myocardial infarction
Divisions of Cardiology and Medicine, Department of Medicine, University of Leicester, Leicester, UK
Objectives: To prospectively investigate whether the PlA2 variant of the platelet adhesion molecule glycoprotein IIIa influences the risk of myocardial infarction. Background: The platelet glycoprotein IIb/IIIa receptor plays an important role in platelet aggregation. The IIIa polypeptide is polymorphic due to a single base change at position 1565 resulting in either proline PlA1 or leucine PlA2 at position 33 in the protein. It has recently been reported that the PlA2 variant may be strongly associated with the risk of acute coronary syndromes, particularly in younger subjects. Methods: PlA genotypes of 242 prospectively collected cases of first myocardial infarction admitted to our Coronary Care Unit were compared with those of 209 community-based control subjects. Results: We found no difference in either PlA genotype (P = 0.65) or allele (P = 0.64) frequencies between cases and controls. The PlA2 allele frequency was 18.2 and 19.4% in cases and controls, respectively. The age- and sex-stratified odds ratio for risk of myocardial infarction associated with the PlA2 allele was 0.89 (95% CI 0.58–1.37, P = 0.65) and remained non-significant when the analysis was confined to subjects under the age of 60 (odds ratio 0.77, 95% CI 0.38–1.56, P = 0.44). There was no interaction between PlA2 and other coronary risk factors. For cases, the age at myocardial infarction was not different between those carrying the PlA2 allele and those not (66.3 ± 10.8 vs. 65.6 ± 11.7 years, P = 0.63). Conclusions: We conclude that, in our subjects, the PlA2 variant of platelet glycoprotein IIIa is not an important risk factor for myocardial infarction.
KEYWORDS Myocardial infarction; Platelets; Integrins; Glycoprotein IIb/IIIa; Human; Genetics; DNA polymorphism
* Corresponding author. Department of Cardiology, Clinical Sciences Wing, Glenfield General Hospital, Groby Road, Leicester LE3 9QP, UK. Tel.: (+44-116) 2563038; Fax: (+44-116) 2875792.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Papp, V. Havasi, J. Bene, K. Komlosi, L. Czopf, E. Magyar, C. Feher, G. Feher, B. Horvath, Z. Marton, et al. Glycoprotein IIIA Gene (PlA) Polymorphism and Aspirin Resistance: Is There Any Correlation? Ann. Pharmacother., June 1, 2005; 39(6): 1013 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Schulman Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, October 20, 2004; 292(15): 1875 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Braunstein, D. W. Kershner, P. Bray, G. Gerstenblith, S. P. Schulman, W. S. Post, and R. S. Blumenthal Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women Chest, March 1, 2002; 121(3): 906 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Benze, J. Heinrich, H. Schulte, S. Rust, U. Nowak-Gottl, M.-C. Tataru, E. Kohler, G. Assmann, and R. Junker Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men Eur. Heart J., February 2, 2002; 23(4): 325 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Feng, K. Lindpaintner, M. G. Larson, C. J. O'Donnell, I. Lipinska, P. A. Sutherland, M. Mittleman, J. E. Muller, R. B. D'Agostino, D. Levy, et al. Platelet Glycoprotein IIIa PlA Polymorphism, Fibrinogen, and Platelet Aggregability: The Framingham Heart Study Circulation, July 10, 2001; 104(2): 140 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Bennett, F. Catella-Lawson, A. R. Rut, G. Vilaire, W. Qi, S. C. Kapoor, S. Murphy, and G. A. FitzGerald Effect of the PlA2 alloantigen on the function of {beta}3-integrins in platelets Blood, May 15, 2001; 97(10): 3093 - 3099. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.H Walter, V Schachinger, M Elsner, S Mach, S Dimmeler, W Auch-Schwelk, and A.M Zeiher Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene Eur. Heart J., April 1, 2001; 22(7): 587 - 595. [Abstract] [PDF] |
||||
![]() |
J. Mikkelsson, M. Perola, P. Laippala, A. Penttila, and P. J. Karhunen Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1317 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kastrati, W. Koch, M. Gawaz, J. Mehilli, C. Bottiger, K. Schomig, N. von Beckerath, and A. Schomig PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement J. Am. Coll. Cardiol., July 1, 2000; 36(1): 84 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Lane and P. J. Grant Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease Blood, March 1, 2000; 95(5): 1517 - 1532. [Full Text] [PDF] |
||||
![]() |
D. Feng, K. Lindpaintner, M. G. Larson, V. S. Rao, C. J. O'Donnell, I. Lipinska, C. Schmitz, P. A. Sutherland, H. Silbershatz, R. B. D'Agostino, et al. Increased Platelet Aggregability Associated With Platelet GPIIIa PlA2 Polymorphism : The Framingham Offspring Study Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 1142 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kastrati, A. Schomig, M. Seyfarth, W. Koch, S. Elezi, C. Bottiger, J. Mehilli, K. Schomig, and N. von Beckerath PlA Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement Circulation, March 2, 1999; 99(8): 1005 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gonzalez-Conejero, M. L. Lozano, J. Rivera, J. Corral, J. A. Iniesta, J. M. Moraleda, and V. Vicente Polymorphisms of Platelet Membrane Glycoprotein Ibalpha Associated With Arterial Thrombotic Disease Blood, October 15, 1998; 92(8): 2771 - 2776. [Abstract] [Full Text] [PDF] |
||||







